Aberdeen Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $63.3M | Sell |
101,566
-19,778
| -16% | -$13.5M | 0.09% | 180 |
|
|
2026
Q1 | $93.8M | Sell |
121,344
-40,394
| -25% | -$30.9M | 0.15% | 124 |
|
|
2025
Q4 | $125M | Buy |
161,738
+10,235
| +7% | +$6.95M | 0.19% | 100 |
|
|
2025
Q3 | $85.2M | Sell |
151,503
-52,247
| -26% | -$29.5M | 0.13% | 136 |
|
|
2025
Q2 | $107M | Sell |
203,750
-41,447
| -17% | -$23.1M | 0.18% | 107 |
|
|
2025
Q1 | $156M | Buy |
245,197
+56,746
| +30% | +$39M | 0.3% | 64 |
|
|
2024
Q4 | $133M | Buy |
188,451
+1,740
| +0.9% | +$1.46M | 0.25% | 87 |
|
|
2024
Q3 | $196M | Buy |
186,711
+8,494
| +5% | +$9.45M | 0.36% | 52 |
|
|
2024
Q2 | $187M | Sell |
178,217
-42,032
| -19% | -$40.7M | 0.36% | 52 |
|
|
2024
Q1 | $212M | Buy |
220,249
+349
| +0.2% | +$332K | 0.42% | 51 |
|
|
2023
Q4 | $193M | Buy |
219,900
+186,215
| +553% | +$153M | 0.42% | 52 |
|
|
2023
Q3 | $27.7M | Sell |
33,685
-451
| -1% | -$354K | 0.07% | 257 |
|
|
2023
Q2 | $24.5M | Buy |
34,136
+280
| +0.8% | +$216K | 0.06% | 304 |
|
|
2023
Q1 | $27.8M | Buy |
33,856
+509
| +2% | +$384K | 0.07% | 276 |
|
|
2022
Q4 | $24.1M | Sell |
33,347
-1,367
| -4% | -$1.01M | 0.07% | 301 |
|
|
2022
Q3 | $23.9M | Buy |
34,714
+2,415
| +7% | +$1.52M | 0.07% | 291 |
|
|
2022
Q2 | $19.2M | Buy |
32,299
+3,830
| +13% | +$2.49M | 0.06% | 293 |
|
|
2022
Q1 | $20.1M | Sell |
28,469
-7,388
| -21% | -$4.67M | 0.05% | 304 |
|
|
2021
Q4 | $22.6M | Sell |
35,857
-1,957
| -5% | -$1.2M | 0.05% | 316 |
|
|
2021
Q3 | $23M | Sell |
37,814
-13,891
| -27% | -$8.62M | 0.05% | 319 |
|
|
2021
Q2 | $28.9M | Sell |
51,705
-22,347
| -30% | -$11.3M | 0.06% | 277 |
|
|
2021
Q1 | $35M | Buy |
74,052
+38,151
| +106% | +$18.6M | 0.08% | 237 |
|
|
2020
Q4 | $17.3M | Buy |
35,901
+2,527
| +8% | +$1.36M | 0.04% | 347 |
|
|
2020
Q3 | $18.7M | Sell |
33,374
-4,497
| -12% | -$2.73M | 0.05% | 310 |
|
|
2020
Q2 | $23.6M | Buy |
37,871
+5,107
| +16% | +$2.9M | 0.06% | 269 |
|
|
2020
Q1 | $16M | Sell |
32,764
-199
| -0.6% | -$82.1K | 0.05% | 307 |
|
|
2019
Q4 | $12.4M | Sell |
32,963
-499
| -1% | -$168K | 0.03% | 417 |
|
|
2019
Q3 | $9.28M | Sell |
33,462
-5,497
| -14% | -$1.63M | 0.02% | 458 |
|
|
2019
Q2 | $12.2M | Sell |
38,959
-696
| -2% | -$232K | 0.03% | 468 |
|
|
2019
Q1 | $16.3M | Buy |
39,655
+19,223
| +94% | +$7.92M | 0.04% | 397 |
|
|
2018
Q4 | $7.46M | Sell |
20,432
-407
| -2% | -$149K | 0.02% | 498 |
|
|
2018
Q3 | $8.42M | Buy |
20,839
+2,403
| +13% | +$915K | 0.02% | 523 |
|
|
2018
Q2 | $6.36M | Buy |
18,436
+4,468
| +32% | +$1.4M | 0.01% | 559 |
|
|
2018
Q1 | $4.81M | Sell |
13,968
-306
| -2% | -$106K | 0.01% | 553 |
|
|
2017
Q4 | $5.37M | Buy |
14,274
+522
| +4% | +$211K | 0.01% | 549 |
|
|
2017
Q3 | $6.15M | Buy |
+13,752
| New | +$6.54M | 0.01% | 523 |
|
Other funds holding REGN
Aberdeen Group's REGN Position: Q2 2026 in Review
Aberdeen Group reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2026, selling an estimated $13.5M and leaving 101,566 shares worth $63.3M. The position accounts for 0.09% of the portfolio, ranked #180.
Aberdeen Group first reported a position in REGN in Q3 2017 and has held it in 36 quarters since. The position peaked at $212M in Q1 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Aberdeen Group held 101,566 shares of Regeneron Pharmaceuticals worth $63.3M as of Q2 2026.
- Aberdeen Group sold 19,778 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $13.5M.
- Regeneron Pharmaceuticals made up 0.09% of Aberdeen Group's portfolio in Q2 2026, its #180 holding.
- Aberdeen Group first reported a position in Regeneron Pharmaceuticals in Q3 2017 and has held it in 36 quarters since.
- Aberdeen Group's Regeneron Pharmaceuticals position peaked at $212M in Q1 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.